Article
A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G.
Vaccine - 21 Oct 2020
Riddle Mark S, Maciel Milton, Porter Chad K, Poole Steven T, Gutierrez Ramiro L, Gormley Robert, Laird Renee M, Sebeny Peter J, Dori Kathleen E, Greenleaf Melissa E, Hoq Fahmida, Turiansky George W, Jarell Abel, Hawk Douglas, Tribble David, Savarino Stephen J
Abstract excerpt
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea among travelers and pediatric populations worldwide. The tip-localized adhesin of colonization factor antigen (CFA)/I fimbriae was engineered as a donor strand complemented variant (dscCfaE) and delivered via transcutaneous immunization. Preclinical vaccine testing demonstrated safety, immunogenicity and efficacy. A series of open-label...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.